^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Multikine (leukocyte interleukin injection)

    i
    Other names: BC-IL, buffy coat interleukins
    Associations

    News

    Trials
    Company:
    CEL-SCI, Orient Europharma, Teva
    Drug class:
    IL-2 stimulant, IFNγ stimulant, IL-1 stimulant, IL-6 stimulant, TNFα stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    Biomarkers of neoadjuvant Multikine (LI) treatment outcome in locally advanced head & neck carcinoma (ESTRO 2023)
    Purpose or Objective In a Phase 3, randomized, controlled study, neoadjuvant administration of investigational proinflammatory biologic Multikine (LI,Leukocyte interleukin injection) with CIZ (single low dose cyclophosphamide IV, indomethacin (po tid) and Zinc (po, daily) multivitamins + Standard of Care (SOC) to oral and soft-palate squamous cell carcinoma (SCCHN) subjects, resulted in significantly prolonged overall survival (OS) in the NCCN defined low risk (LR) intent to treat (ITT) population vs SOC alone (IT-MATTERS Study, NCT01265849). Multiple biomarkers (tumor: p16, PDL1, TME: CD4, CD8, CD3, FOXP3, CD20, CD68, CD163, CD1A, immune cells: PD1, CTLA4, PDL1, and CD25), ratios (CD4/CD8, CD8/FOXP3), and combinations proved to be predictive. LI + Surgery + RTx prolongs OS in SCCHN patients with no new Tx options in decades.
    Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    cyclophosphamide • Multikine (leukocyte interleukin injection)
    almost3years
    Brain metastasis mouse models for the evaluation of multikine inhibitors on ROS1-fusion-positive lung cancer (AACR 2022)
    In summary, we established brain metastases lung cancer PDX models as reliable platforms for interrogation of targets and kinetics related mechanism and for drug screening. The use of such techniques will increase our knowledge of the metastatic process and help identify new targets of cancer metastasis.
    Preclinical
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SDC4 (Syndecan 4)
    |
    ROS1 fusion • ROS1 positive • SDC4-ROS1 fusion
    |
    Multikine (leukocyte interleukin injection)